Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 23704092

Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Blood
Publication date
2013 Jul 25
First author
Ross DM

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Blood. 2013 Jul 25;122(4):470-1. doi: 10.1182/blood-2013-06-506097.
    note
    Source null
    related pmid
    23886774
    relationship
    Comment in

Authors and identifiers

  1. name
    Ross DM
    type
    Author
  2. name
    Branford S
    type
    Author
  3. name
    Seymour JF
    type
    Author
  4. name
    Schwarer AP
    type
    Author
  5. name
    Arthur C
    type
    Author
  6. name
    Yeung DT
    type
    Author
  7. name
    Dang P
    type
    Author
  8. name
    Goyne JM
    type
    Author
  9. name
    Slader C
    type
    Author
  10. name
    Filshie RJ
    type
    Author
  11. name
    Mills AK
    type
    Author
  12. name
    Melo JV
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Ross DM
    type
    Author
  2. name
    Branford S
    type
    Author
  3. name
    Seymour JF
    type
    Author
  4. name
    Schwarer AP
    type
    Author
  5. name
    Arthur C
    type
    Author
  6. name
    Yeung DT
    type
    Author
  7. name
    Dang P
    type
    Author
  8. name
    Goyne JM
    type
    Author
  9. name
    Slader C
    type
    Author
  10. name
    Filshie RJ
    type
    Author
  11. name
    Mills AK
    type
    Author
  12. name
    Melo JV
    type
    Author
bibliography ids
  1. nci-bib-95c71166001e8bab02c9df33
book metadata
content sha256
a30e976a6ff57f406183ba2290b460dfc64b4730c1750480383584f765a2f6ec
document type
citation
dois
  1. 10.1182/blood-2013-02-483750
electronic publication date
display
2013 May 23
precision
day
year
2013
evidence scope
bibliographic_metadata_only
id
pubmed:23704092
immutable id
pubmed:23704092@a30e976a6ff57f406183ba2290b460dfc64b4730c1750480383584f765a2f6ec
journal
abbreviation
Blood
issn electronic
1528-0020
issn print
0006-4971
issue
4
name
Blood
nlm unique id
7603509
pages
515-22
volume
122
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Blood. 2013 Jul 25;122(4):470-1. doi: 10.1182/blood-2013-06-506097.
    note
    Source null
    related pmid
    23886774
    relationship
    Comment in
outcomes validated
false
pmid
23704092
provenance
batch id
99e008dabc339d38fd44
provider
NCBI PubMed ESummary
record sha256
1076a2386f1c57ee3cd9507f3b71fa17b1f75950f98c9b09a370e019c8c2ff00
response sha256
804916232567480946eda9a00aff276bc44fd9a6d15d9336e773a9c803123d39
retrieved at
2026-09-09T23:46:55.094762+00:00
publication date
display
2013 Jul 25
precision
day
year
2013
publication types
  1. Clinical Trial
  2. Journal Article
  3. Multicenter Study
  4. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/23704092/
title
Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study.

Preserved source evidence · Not medical advice